In QuotedData’s other news 8 July 2019
- Syncona (SYNC), a healthcare company focused on founding, building and funding global leaders in life science, has noted the announcement that its portfolio company, Freeline Therapeutics, has presented 52-week data from the first cohort of two patients in the ongoing B-AMAZE FLT180a Phase 1/2 trial in Haemophilia B at the International Society on Thrombosis and Haemostasis (ISTH) congress in Melbourne, Australia, 6-10 July 2019.
We also have stories on Aquila European Renewables Income, Highbridge Multi-Strategy, Symphony, Martin Currie Asia Unconstrained, and Real Estate Investors.